drugset

drugset / Trial / NCT06633341

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

NCT06633341 ↗

Phase 0 Recruiting 30 enrolled Zhejiang University Yake Biotechnology Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma

Timeline

Start: 2024-10-20
Primary completion: 2027-10-20
Completion: 2027-10-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD5 CAR T-cells	Cell therapy	—	Intravenous

Indications